Arena Pharmaceuticals, Inc. | ||||
Condensed Consolidated Balance Sheet Data | ||||
(In thousands) | ||||
March 31, 2010 | December 31, 2009 | |||
(unaudited) | * | |||
Assets | ||||
Cash, cash equivalents & short-term investments | $ 107,615 | $ 115,449 | ||
Accounts receivable | 1,960 | 1,415 | ||
Other current assets | 4,489 | 4,409 | ||
Land, property & equipment, net | 94,451 | 95,445 | ||
Acquired technology & other non-current assets | 18,754 | 19,560 | ||
Total assets | $ 227,269 | $ 236,278 | ||
Liabilities and Stockholders' Equity | ||||
Accounts payable and accrued liabilities | $ 10,609 | $ 15,884 | ||
Total deferred revenues | 4,049 | 4,086 | ||
Total derivative liabilities | 5,223 | 6,642 | ||
Total note payable to Siegfried | 8,956 | 9,143 | ||
Note payable to Deerfield** | 51,828 | 47,906 | ||
Total lease financing obligations & other long-term liabilities | 77,869 | 78,050 | ||
Total stockholders' equity | 68,735 | 74,567 | ||
Total liabilities & stockholders' equity | $ 227,269 | $ 236,278 | ||
* The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date. ** The outstanding principal balance of the note payable to Deerfield at March 31, 2010 and December 31, 2009 was $90.0 million. | ||||
